PositoAI/ US/ Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc.

NasdaqCM: GYRE · Healthcare

Positivity Index

#3,122 / 6,774

Global

#1,234 / 4,000

United States

Positivity Score

20,847

Rank→

Overview Go Deep Penta Pattern Funda News For this company Histo

PosiRed: no active red flags

Gyre Therapeutics, Inc. — Overview & Financial Snapshot

Gyre Therapeutics, Inc. (NasdaqCM: GYRE) is a Healthcare company, ranked #3,122 of 6,774 companies globally and #1,234 of 4,000 in United States on PositoAI, with a Positivity Score of 20,847. Its market capitalisation is ₹5,865.05 Cr ($621.36M), P/E ratio is -23.4 and P/B ratio is 5.76. It has no active red flags (PosiRed) or yellow flags (PosiYellow) on record.

For financial statements, ratio trends and score history, Go Deep →

Top-ranked Healthcare companies

#3 Dogwood Therapeutics, Inc. 27,827 #8 Impact BioMedical Inc. 26,149 #13 Onconetix, Inc. 25,902 #15 Revelation Biosciences, Inc. 25,780 #18 Vyome Holdings, Inc. 25,696

— Nothing to show —

OpenAI is reading recent news...

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

P/B Ratio 5.76

P/E Ratio -23.4

D/E Ratio 0.02

ROE -17.44%

Owes vs Owns ? 0.28× Low $0.28 owed for every $1 it owns · balance sheet Jun 2026

Dividend Yield 0.00%

Trailing EPS ₹-23.60$-0.25

Forward EPS ₹5.66$0.06

Beta 4.74

Market Cap ₹5,865.05 Cr$621.36M

What these numbers mean →

What does Gyre Therapeutics, Inc. do?

What is Gyre Therapeutics, Inc.'s P/E and P/B ratio?

Gyre Therapeutics, Inc. has a P/E ratio of -23.4 and a P/B ratio of 5.76.

What is Gyre Therapeutics, Inc.'s debt-to-equity ratio?

Gyre Therapeutics, Inc. has a debt-to-equity ratio of 0.02.

How much does Gyre Therapeutics, Inc. owe compared with what it owns?

Gyre Therapeutics, Inc. owes $0.28 for every $1 it owns (balance sheet Jun 2026), which is low.

What is Gyre Therapeutics, Inc.'s Positivity rank?

Gyre Therapeutics, Inc. is ranked #3,122 of 6,774 companies globally and #1,234 of 4,000 in United States on PositoAI, with a Positivity Score of 20,847.

Does Gyre Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?

No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Gyre Therapeutics, Inc..

Where can I read the latest news about Gyre Therapeutics, Inc.?

Recent headlines about Gyre Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.

Does Gyre Therapeutics, Inc. have a PositoAI PosiShot or QR code?

Yes. A dated PosiShot of Gyre Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.

0 / 1000

🔒 Private — stored only in this browser, never sent to PositoAI. Clear anytime in Settings.